T1	Participants 340 510	A randomized controlled clinical study on rAd-p53 combined with RT in 42 patients with NPC was compared with a control group of 40 patients with NPC treated with RT alone
T2	Participants 512 621	In the group receiving rAd-p53 combined with RT, rAd-p53 was intratumorally injected once a week for 8 weeks.
T3	Participants 719 787	Patients and tumors were monitored for adverse events and responses.
